-$0.32 EPS Expected for Iovance Biotherapeutics Inc (IOVA) This Quarter

Wall Street brokerages expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to post earnings per share (EPS) of ($0.32) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.34). Iovance Biotherapeutics posted earnings per share of ($0.20) during the same quarter last year, which would indicate a negative year-over-year growth rate of 60%. The company is scheduled to announce its next quarterly earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.35) per share for the current financial year, with EPS estimates ranging from ($1.39) to ($1.23). For the next financial year, analysts expect that the company will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.49) to ($1.08). Zacks’ EPS calculations are a mean average based on a survey of analysts that follow Iovance Biotherapeutics.

A number of research firms have commented on IOVA. HC Wainwright set a $22.00 target price on Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Thursday, February 8th. Jefferies Group increased their target price on Iovance Biotherapeutics to $31.00 and gave the stock a “buy” rating in a report on Friday, February 9th. ValuEngine raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Finally, Oppenheimer increased their target price on Iovance Biotherapeutics from $13.00 to $19.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $18.75.

Iovance Biotherapeutics (IOVA) traded up $0.55 during trading hours on Wednesday, reaching $17.95. The company’s stock had a trading volume of 831,741 shares, compared to its average volume of 1,732,197. Iovance Biotherapeutics has a 52 week low of $4.45 and a 52 week high of $18.30. The company has a market cap of $1,478.97, a P/E ratio of -13.81 and a beta of 5.89.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG lifted its holdings in shares of Iovance Biotherapeutics by 2.6% in the 4th quarter. Deutsche Bank AG now owns 140,536 shares of the biotechnology company’s stock worth $1,123,000 after purchasing an additional 3,627 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Iovance Biotherapeutics by 12.6% in the 4th quarter. The Manufacturers Life Insurance Company now owns 45,817 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 5,110 shares during the last quarter. Ellington Management Group LLC lifted its holdings in shares of Iovance Biotherapeutics by 39.1% in the 4th quarter. Ellington Management Group LLC now owns 19,200 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 5,400 shares during the last quarter. American International Group Inc. lifted its holdings in shares of Iovance Biotherapeutics by 17.0% in the 4th quarter. American International Group Inc. now owns 41,470 shares of the biotechnology company’s stock worth $332,000 after purchasing an additional 6,039 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in shares of Iovance Biotherapeutics by 13.5% in the 4th quarter. California State Teachers Retirement System now owns 97,044 shares of the biotechnology company’s stock worth $776,000 after purchasing an additional 11,559 shares during the last quarter. 64.53% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “-$0.32 EPS Expected for Iovance Biotherapeutics Inc (IOVA) This Quarter” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/17/0-32-eps-expected-for-iovance-biotherapeutics-inc-iova-this-quarter.html.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply